Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2016-04-14 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2015年度利润分配预案
Notice of Dividend Amount Classification · 95% confidence The document is titled as a 2015年度利润分配预案, which translates to '2015 Annual Profit Distribution Plan'. It details the company's net profit for 2015, undistributed profits, and a proposed dividend distribution plan (cash dividend of 3 yuan per 10 shares). The document focuses on dividend distribution and capital reserve conversion to share capital, which is a typical dividend announcement. The document length is short (772 characters), and it does not contain full financial statements or comprehensive financial analysis. It is not an annual report or earnings release but a notice about dividend amount and distribution details. Therefore, the document fits the category of Notice of Dividend Amount (DIV).
2016-04-14 Chinese
关于使用自有资金对子公司实施委托贷款公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by a company (葵花药业集团股份有限公司) regarding the use of its own funds to provide entrusted loans to its subsidiaries. It details the loan amounts, purposes, terms, repayment methods, and risk control measures. It also includes independent directors' opinions and board resolutions related to this financing activity. There is no indication that this is a full financial report, audit report, or earnings release. Instead, it is an update on a capital/financing activity involving internal loans to subsidiaries. The document length is over 6,000 characters and contains substantive details about the financing arrangement, which fits the category of Capital/Financing Update rather than a simple announcement or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-04-14 Chinese
2015年财务决算报告
Annual Report Classification · 95% confidence The document is titled '2015 年财务决算报告' which translates to '2015 Financial Final Report' and includes detailed financial data such as total assets, asset-liability ratio, equity attributable to shareholders, revenue, operating profit, and net profit for the year ending December 31, 2015. It also mentions an audit report with an unqualified opinion from an accounting firm. The content is a comprehensive yearly financial performance report, consistent with an Annual Report (10-K) rather than a brief announcement or certification. The document length is short but contains substantive financial data, not just a notice or announcement. Therefore, it fits the definition of an Annual Report (10-K). FY 2015
2016-04-14 Chinese
2015年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2015年度独立董事述职报告" which translates to "2015 Annual Independent Directors' Work Report." It contains detailed reports from multiple independent directors about their attendance at board meetings and shareholders' meetings, their independent opinions on various company matters, their committee work, on-site investigations, and efforts to protect shareholders' rights. The content is focused on the independent directors' duties, opinions, and activities during the year 2015. This type of document is a formal report by independent directors on their work and oversight during the fiscal year, which is a specific type of management or board-related report. It is not a full annual report (10-K), nor is it an announcement or proxy statement. It is not a call transcript, audit report, or any other category. The best fitting category is Board/Management Information (MANG), as it relates to board members' activities and governance oversight. The document length is substantial (over 13,000 characters), indicating it is a full report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2016-04-14 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制鉴证报告' (Internal Control Assurance Report) and includes a detailed internal control self-evaluation report for the year ending December 31, 2015. It is issued by an accounting firm (瑞华会计师事务所) and addresses the effectiveness of internal controls related to financial reporting. The content includes detailed descriptions of internal control evaluation scope, principles, deficiencies, and corrective actions, which are typical of an audit or assurance report on internal controls rather than a full annual report or financial statement. The document length is substantial (13,372 characters), indicating it is the report itself, not just an announcement. It does not contain full financial statements or earnings highlights, so it is not an Annual Report (10-K) or Earnings Release (ER). It is not a management or governance report, nor a regulatory filing or announcement. The document fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on internal controls. Therefore, the correct classification is AR with high confidence. FY 2015
2016-04-14 Chinese
募集资金管理制度（2016年4月）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '募集资金管理制度' (Fundraising Capital Management System) of a company, 葵花药业集团股份有限公司. It extensively discusses the management, usage, supervision, and regulatory compliance related to the company's raised funds from securities issuance. It references relevant laws, regulatory requirements, and internal procedures for managing raised capital, including the establishment of special accounts, approval processes, usage restrictions, and reporting obligations. There is no indication that this is an announcement, a financial report, or a certification. Instead, it is a governance document outlining internal rules and procedures related to capital management. Therefore, the document best fits the category of Governance Information (CGR).
2016-04-14 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.